- Home
- ATXS vs ORGO Comparison
ATXS vs ORGO Comparison
Compare ATXS & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- ORGO
- Stock Information
- Founded
- ATXS 2008
- ORGO 1985
- Country
- ATXS United States
- ORGO United States
- Employees
- ATXS N/A
- ORGO N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- ORGO Health Care
- Exchange
- ATXS Nasdaq
- ORGO Nasdaq
- Market Cap
- ATXS 401.2M
- ORGO 384.4M
- IPO Year
- ATXS 2015
- ORGO N/A
- Fundamental
- Price
- ATXS $5.86
- ORGO $3.25
- Analyst Decision
- ATXS Strong Buy
- ORGO Buy
- Analyst Count
- ATXS 7
- ORGO 2
- Target Price
- ATXS $32.43
- ORGO $5.50
- AVG Volume (30 Days)
- ATXS 479.1K
- ORGO 911.8K
- Earning Date
- ATXS 08-11-2025
- ORGO 08-07-2025
- Dividend Yield
- ATXS N/A
- ORGO N/A
- EPS Growth
- ATXS N/A
- ORGO N/A
- EPS
- ATXS N/A
- ORGO N/A
- Revenue
- ATXS N/A
- ORGO $458,760,000.00
- Revenue This Year
- ATXS N/A
- ORGO $2.62
- Revenue Next Year
- ATXS N/A
- ORGO $12.46
- P/E Ratio
- ATXS N/A
- ORGO N/A
- Revenue Growth
- ATXS N/A
- ORGO 5.35
- 52 Week Low
- ATXS $3.56
- ORGO $2.28
- 52 Week High
- ATXS $12.92
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- ATXS 62.16
- ORGO 48.02
- Support Level
- ATXS $5.43
- ORGO $3.08
- Resistance Level
- ATXS $5.97
- ORGO $3.71
- Average True Range (ATR)
- ATXS 0.44
- ORGO 0.21
- MACD
- ATXS 0.06
- ORGO 0.07
- Stochastic Oscillator
- ATXS 82.37
- ORGO 55.45
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.